Qiagen (QGEN) Reports In-Line Q4 EPS, Revenues Miss

Qiagen (NYSE: QGEN) reported Q4 EPS of $0.40, in-line with the analyst estimate of $0.40. Revenue for the quarter came in at $403.2 million versus the consensus estimate of $408.56 million.

“We are pleased with the achievements of QIAGEN in 2018, delivering a performance in line with our outlook for net sales growth and exceeding our target for adjusted earnings per share. Our teams made outstanding progress on creating what we believe is one of the most dynamic and disruptive portfolios of Sample to Insight solutions for molecular testing,” said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V. “Although we exceeded our target for adjusted diluted EPS, sales for the fourth quarter were softer, due mainly to changes agreed upon during the quarter in a third-party R&D project in Applied Testing linked to the divestment of the veterinary testing assay portfolio and our decision to accelerate the reduction of low-margin, third-party instrument service contracts to ensure service capacity for several new QIAGEN instrument systems, such as QIAstat-Dx and NeuMoDx.”

For earnings history and earnings-related data on Qiagen (QGEN) click here.

You May Also Be Interested In

• AeroVironment restates quarterly financials, citing $89M goodwill error
• Transcat names Roy Simmons as chief strategy officer
• Fermi board disputes ex-CEO's claims in shareholder consent fight